Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is one of the most common diseases affecting aging men, but the underlying molecular features of BPH remain poorly understood, and therapeutic options are limited. Here we employed a comprehensive molecular investigation of BPH, including genomic, transcriptomic and epigenetic profiling of 18 BPH cases. At the molecular level, we found no evidence of neoplastic features in BPH: no evidence of driver genomic alterations, including low coding mutation rates, mutational signatures consistent with aging tissues, minimal copy number alterations, and no genomic rearrangements.
Introduction
Benign prostatic hyperplasia (BPH) is a common disease, affecting nearly all men as they age 1, 2, 3, 4, 5 . BPH frequently results in bladder outlet obstruction with concomitant lower urinary tract symptoms or infections, and more rarely bladder decompensation and renal failure 3, 6, 7 . The prevalence of BPH increases with age, with BPH symptoms reported by roughly half of men at age 50 1, 2, 3, 4, 7 . Approved medical therapies for BPH are limited to alpha-blockers, 5-alpha reductase inhibitors, and PDE5 inhibitors 8, 9, 10 . However, many patients fail medical therapies, and require surgical intervention 11 . Histologically, BPH is characterized as the overgrowth of stromal and epithelial cells, and it occurs in the transitional zone of prostate 1 . Currently, many BPH studies have focused on risk factors of BPH 12, 13, 14, 15 , while the underlying molecular features of BPH remain understudied 3, 9, 16, 17, 18, 19 and molecular data is relatively scarce 20, 21 . Moreover, BPH has been described as "the most common benign tumor in men", and is commonly referred to as an adenoma, but unlike many malignant 22, 23 and benign neoplasms 24, 25, 26 , it is unknown whether BPH is a neoplastic process 3, 7, 18, 19, 20 . In this study, we performed a comprehensive investigation of 18 BPH cases via next-generation sequencing technology (Table S1 ). We selected samples from patients with very large prostates (top percentile and greater than 100cc, Table S1 and Figure 1A) , based on the rationale that these "extreme outlier" were more likely to harbor biologically informative events 27, 28 .
Results
To define the landscape of genomic alterations in BPH, we performed whole genome sequencing (WGS), whole exome sequencing (WES) and SNP arrays on 18 BPH cases and matched controls (Table S1 ). The number of somatic coding mutations (SNV) ranged from 0.1 to 1 per megabase (Mb) ( Table S2) . As compared to neoplastic diseases (benign and malignant) 24, 25, 26 , BPH samples harbored fewer SNVs ( Figure 1B) , and there were no recurrent SNVs to suggest driver alterations. To understand underlying mutational processes, we examined mutational signatures 29 across all BPH cases, and found BPH was highly associated with mutation signature 1 29 , which included C>T substitutions at NpCpG trinucleotides ( Figures 1C and 1D ). This signature has been shown to correlate with age 29, 30 , consistent with the age-related onset of BPH 1, 2, 3, 4, 7 .
Moreover, BPH samples harbored minimal copy number alterations, and the fraction of altered genome was far lower than seen in primary prostate cancer 23 and other neoplastic diseases ( Figures 1E and 1F , Table S4 and S5). Also unlike primary prostate cancer 23, 31 , analyses of structural variants in WGS revealed no genomic rearrangements in BPH (Figures 1G and S1). Together, these data show no evidence of driver genomic alterations in BPH, inconsistent with a neoplastic disease process.
We next examined the transcriptional landscape of BPH using RNA-seq. Because BPH, by its very nature has no "adjacent normal" tissue, we compared the gene expression profiles from BPH samples with histologically normal transition zone tissue sampled from age-matched controls (Figure 2A ). We identified a BPH transcriptional signature that included 392 differentially expressed genes between BPH and control samples ( Figure 2B and Table S6 ). When compared to control samples from the normal peripheral zone, this transcriptional signature was BPH specific, and not specific to transition zone tissue ( Figure S2 ). We next validated this BPH transcriptional signature using two independent study cohorts 21, 32 , and again found reliable clustering of BPH samples ( Figures 2C and 2D ) with similar upregulation of BMP5 identified (Table S6 ).
Having defined and validated a robust set of genes altered in BPH, we explored the signaling pathways deregulated using gene set enrichment analysis (GSEA) 33 ( Figure   2E ). Interestingly, multiple signatures related to inactivation of KRAS signaling were observed in our dataset, with concordance in an independent cohort ( Figure 2E ), and again inconsistent with a neoplastic process. In addition, we observed AR signaling downregulated in BPH ( Figure 2F ), consistent with previous findings that AR signaling disruption correlated with prostate inflammation and BPH pathogenesis 34, 35 .
Next, we investigated the epigenetic landscape of BPH by defining the DNA methylation profile of 18 BPH samples and 5 controls from normal transition zone tissue using ERRBS (Enhanced Reduced Representation Bisulfite Sequencing). We identified 92,046 hypermethylated CpGs and 10,117 hypomethylated CpGs across different genomic regions in BPH, with hypermethylation being the dominant signal across all genomic regions, even when controlling for bias of CpG-rich loci (Figures 2G, 2H and S3). We defined a methylation signature for BPH that included 696 differentially methylated CpGs in promoter regions ( Figure 2I and Table S7 ). Consistent with DNA methylation as a major mechanism of transcriptional control in BPH, we found negative correlation between promoter methylation and gene expression ( Figure 2J ). For instance, HOXD1 was both underexpressed and hypermethylated at the promoter in BPH specimens, consistent with the downregulation of AR signaling pathway found in BPH 36, 37 ( Figures   2E and S3 ).
Identifying distinct molecular subtypes in human disease has provided insight into important biological and clinical phenomena. We therefore performed integrative analysis using transcriptional and methylation profiling, and identified two distinct BPH subtypes ( Figure 3A and Tables S6-7), supporting robust biologically distinct subgroups across different data types. To validate distinct subtypes in BPH, we tested our signature via k-means clustering in two independent cohorts 20, 21 , and identified nearly identical subgroups (Figures 3C, 3E and Table S8 ), further supporting the robustness of these subgroups across data types and sources. We then examined the molecular and clinical features of these two groups. One subgroup (BPH-A) was enriched in stromal signatures 38 ( Figures 3B and S4 ), again in the validation cohort as well ( Figure 3D and S5). Integrating the stromal cell signatures from single cell RNA-seq on normal prostate tissue 39 further confirmed the stromal enrichment in BPH-A subgroup ( Figure S7 ). Of note, there was no clear enrichment of stromal cell content visible on histopathology analysis of these samples, suggesting that molecular characterization provided independent information ( Figure S8 ).
The second subgroup (BPH-B) was enriched for patients with obesity (BMI >30) and hypertension ( Figure 3D ), potentially suggesting distinct pathobiology. Consistent with this, gene set enrichment analysis between the two subgroups demonstrated significant differences among metabolism related signatures, such as fatty acid and amino acid metabolism ( Figure 3D ). Positive correlation of metabolism dysregulation between the two subgroups extended to both cohorts ( Figures 3D and S6) , consistent with the clinical associations with obesity and hypertension. We then explored signaling pathways within each subgroup to further understand the underlying biology. As compared to control samples, we found differential expression of metabolism related genes predominantly in BPH-A samples ( Figures 3F and 3G , Tables S10 and S11), consistent with the metabolism difference between two subgroups. Unbiased gene set enrichment analysis (GSEA) showed multiple deregulated pathways for each subgroup, with many pathways were negatively correlated between two subgroups ( Figure 3H and Table S12 ), reinforcing distinct biology. Together these molecular data suggested two distinct biological categories of BPH -one with stromal-like molecular features, and the other associated with deregulation of metabolic pathways that presents in patients with underlying metabolic disturbances.
To nominate potential subtype specific therapeutic options, we utilized the Connectivity Map 40, 41 analysis ( Figure 4A and Table S13 ), which uses transcriptional expression data to probe relationships between diseases, cell physiology, and therapeutics. Strikingly, we found 50% of nominated compounds in BPH-A subgroup were related to inhibition of mTOR signaling ( Figure 4B ), and the subgroup enrichment of mTOR signaling was validated in two independent cohorts ( Figure 4C ), consistent with prior isolated reports in model systems 42, 43, 44 . To interrogate the potential effect of mTOR treatment on the prostate, we examined prostate size on cross-sectional imaging in patients taking mTOR inhibitors. We identified 425 male patients who had been prescribed an mTOR inhibitor (everolimus, sirolimus, or temsirolimus) for transplant or treatment of a non-prostate malignancy. We then reviewed these patient's charts to identify men with accessible CT imaging including the pelvis before and after treatment, identifying 47 such subjects. CT scans from these 47 subjects and 12 men with serial imaging for nephrolithiasis (negative controls) then underwent blinded review and assessment of prostate size ( Figure S9 ). Of these men, 17/47 had a prostate size decrease based on pre-established thresholds (12.5% decrease from baseline), all of whom were on an mTOR inhibitor ( Figures 4D and 4F ).
None of the nephrolithiasis patients showed a significantly prostate size decrease. A higher proportion of patients taking Everolimus had a decrease in prostate size (pvalue=0.02) than Sirolimus (pvalue =0.06), compared to kidney stone patients (0%) ( Figure 4E ). Similar trends were seen in the effect of mTOR inhibitors on absolute crosssectional area ( Figure S10 ). Overall, these data suggest that subgroup BPH-A represents a biologically distinct subtype of disease preferentially dependent on mTOR signaling, and mTOR inhibition could serve as a novel therapeutic option.
Discussion
In summary, we report the first comprehensive, multi-level molecular investigation of BPH, including genomic, transcriptomic and epigenomic profiling. While dogma often suggests BPH represents a benign neoplastic process, we find no evidence of somatic genomic alterations, unlike benign neoplasms like such as frequent MED12 mutations in breast fibroadenomas 24, 25 and uterine fibromas 45 or FRK mutations in hepatocellular adenomas 26 , and BPH exhibited an age-related mutation signature, consistent with the higher prevalence in older patients as opposed to underlying oncogenic processes.
Furthermore, unlike the global hypomethylation signature in neoplastic diseases 46, 47, 48 , the DNA methylation landscape in BPH was dominated by hypermethylation. Together, our genomic and epigenomic data argues against BPH arising from a neoplastic disease process.
By integrating the transcriptional and DNA methylation data, we identified and validated two molecular subgroups in BPH, one characterized by a stromal signal (despite no clear differences in histology), and the other associated with hypertension and obesity, which was consistent with metabolism dysregulation between these two subgroups. Moreover, the altered signaling pathways of each subgroup comparing with control samples were related to the metabolism regulation and hypertension. Finally, we nominated potential therapeutic compounds for each BPH subgroup, and found that mTOR inhibitors may be preferentially active in one subgroup. By validating mTOR treatment on our institutional patient cohort, we found 17/47 patients treated with mTOR inhibitors showed the significant decreases on prostate size based on CT scan imaging, and no decrease found in patients without mTOR inhibitor. Overall, our findings provide critical insight into the underlying pathobiology of BPH, identify for the first time distinct molecular subgroups, and introduce a paradigm of precision therapy for a disease that affects the majority of aging men.
Methods

Samples collection.
Patients with BPH (benign prostatic hyperplasia) were prospectively enrolled for and breast fibroadenomas (BFT) were derived from published studies 24, 25, 26 .
Copy number analysis.
DNA from BPH and matched control samples from blood tissue were analyzed by Affymetrix SNP 6.0 arrays to detect the regions of somatic copy number alteration.
Quality control, segmentation and copy number analysis were performed as previously described 23 . The copy number alterations of malignant diseases were downloaded from TCGA portal (https://portal.gdc.cancer.gov/). Segments with log 2 -ratio >0.3 were defined as genomic amplifications, and log 2 -ratio <-0.3 were defined as genomic deletions.
RNA-seq platform, data procession and analysis pipeline.
RNA-seq library for BPH and control samples from patients without BPH symptoms
were generated using Poly-A and Ribo-Zero kits. RNA-seq was performed in the 41 with the top most overexpressed and underexpressed genes as the input, and CMAP score >90 were used to select the nominated compounds.
Enhanced Reduced Representation Bisulfite Sequencing (ERRBS) platform, data procession and analysis pipeline.
Genomic DNA was isolated from BPH and control samples, and submitted to the Epigenomics Core of Weill Cornell Medicine under standard protocol and pipeline. The Epigenomics Core facility in Weill Cornell Medicine supported alignment and methylation extraction for ERRBS data 65 . Differentially methylated CpGs (DMCs) were identified by methylKit 66 and RRBSeeqer 67 (false discovery rate =5%, and methylation difference more than 10%). Differentially methylated regions (DMRs) were defined as regions containing at least five DMCs within 250bp window. Genomic regions for CpGs were defined according to the following definitions. CGIs (CpG islands) were defined using annotations from RefSeq. CGI shores were defined as the regions encompassing 1kb upstream and downstream of known CGIs. Non-CGIs were defined as regions at least 10kb away from known CGIs. Promoters were defined as the regions encompassing 2kb upstream and downstream of the TSS (transcription start site) of RefSeq genes.
Promoter methylation for each gene was calculated by averaging the methylation levels of all CpGs covered in the promoter.
Effect of mTOR inhibition on prostate size
We searched our electronic medical record to identify all adult male patients who received therapy with an mTOR inhibitor (Sirolimus, Everolimus, or Temsirolimus) using our institutional i2b2 search tool (IRB 1510016681R003) ( Figure S9 ). Records were manually reviewed in order to identify individuals with CT imaging containing the pelvis before and after therapy. The most proximate CT scan prior to the initiation of therapy and the CT scan as close to 6 months after the initiation of therapy were used. This interval was chosen based on the known time course of prostate size changes in response to finasteride 68 . As negative controls, we identified 12 kidney stone patients over age 35 at the time of baseline CT who had serial CT imagining including the pelvis who did not take 5-alpha-reductase inhibitors, have prostate cancer, recurrent urinary tract infections, or a history of prostatic surgery. In order to establish a signal window, we performed an initial unblinded pilot including patients who underwent androgen deprivation therapy as a positive control and kidney stone patients as a negative control. We determined that a decrease in prostate size of >12.5% in sequential CT scans would have captured 9/10 androgen deprivation therapy patients from CT scans spaced ~6 months apart, and would be >2 standard deviations from the mean decrease in prostate size of the kidney stone patients.
We then extracted accession numbers from both kidney stone and mTOR inhibitor patients and using a random number generator placed them in arbitrary order for review. A radiologist then reviewed these scans by using accession numbers unaware of treatment assignment (mTOR inhibitor or kidney stone) or whether it was a baseline or follow up study. The prostate was measured in two dimensions in the axial slice with the greatest apparent prostate area, with area computed as anterior-posterior x transverse measurements. When unclear, the prostate was measured in two axial slices and the maximum area utilized.
Following review, scans were then re-identified, and subjects with a baseline axial prostate size <1000 mm 2 were excluded from further analysis. Subjects where the blinded review showed a >12.5% decrease in area, defined as initial area-follow up area)/ initial area, and then underwent a subsequent blinded review by an urologist (JS). Agreement was necessary between both reviews for a decrease to be considered true: when urology review did not identify a decrease >12.5% and this differed from radiology review by <20% urology review was prioritized. For subjects where both reviewers agreed on the decrease in area, initial radiology review dimensions were utilized. When there was a >20% discrepancy in measurements (irrespective of degree), scans were re-reviewed blinded by radiology, blinded, and these measurements utilized.
Data Availability
The dbGap submission of WGS and WES data is in process. The SNP array data has been deposited in GEO under the accession GSE124187, RNA-seq data has been deposited in GEO under the accession GSE132714, and ERRBS data has been deposited in GEO under the accession GSE123111. 
